Rimeporide    (DrugBank: Rimeporide)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy5

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002530-50-IT
(EUCTR)
19/01/201722/08/2018A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy (DMD)A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy (DMD) - RIM4DMD Distrofia Muscolare di Duchenne (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
ESPERARE FOUNDATIONNULLNot Recruiting Female: no
Male: yes
20Phase 1France;Spain;United Kingdom;Italy
2NCT02710591
(ClinicalTrials.gov)
March 201626/1/2016Rimeporide in Patients With Duchenne Muscular DystrophyA Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular DystrophyMuscular Dystrophy, DuchenneDrug: RimeporideEspeRare FoundationNULLCompleted6 Years14 YearsMale20Phase 1France;Italy;Spain;United Kingdom
3EUCTR2015-002530-50-FR
(EUCTR)
18/12/201511/09/2015Rimeporide in patients with Duchenne Muscular DystrophyA phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy (DMD)
MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Rimeporide
Product Code: EMD 87580
INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate
Other descriptive name: Rimeporide
INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate
Other descriptive name: Rimeporide
EspeRareNULLNot RecruitingFemale: no
Male: yes
20Phase 1France;Spain;Italy;United Kingdom;Switzerland
4EUCTR2015-002530-50-ES
(EUCTR)
04/11/201525/08/2015Rimeporide in patients with Duchenne Muscular DystrophyA phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. - Rim4DMD Duchenne Muscular Dystrophy (DMD)
MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Rimeporide
Product Code: EMD 87580
INN or Proposed INN: N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate
Other descriptive name: Rimeporide
EspeRareNULLNot RecruitingFemale: no
Male: yes
20Phase 1France;Spain;Italy;United Kingdom;Switzerland
5EUCTR2015-002530-50-GB
(EUCTR)
29/10/201507/09/2015Rimeporide in patients with Duchenne Muscular DystrophyA phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy - RIM4DMD Duchenne Muscular Dystrophy (DMD)
MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Rimeporide
Product Code: EMD 87580
INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate
Other descriptive name: Rimeporide
INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate
Other descriptive name: Rimeporide
EspeRareNULLNot RecruitingFemale: no
Male: yes
20Phase 1France;Spain;Italy;Switzerland;United Kingdom